Table 4.
Multivariable Logistic Regression Analysis to Determine the Effectiveness of Nirmatrelvir/Ritonavir Treatment
| Explanatory Variable | Odds Ratio | 95% CI | P Value |
|---|---|---|---|
| Model 1a | |||
| Treatment | |||
| Nonrecipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.31 | .27–.36 | <.001 |
| Age, per year | 1.09 | 1.08–1.10 | <.001 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.55 | .37–.80 | .003 |
| Vaccination status | |||
| Unvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.53 | .44–.63 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.49 | .41–.59 | <.001 |
| Model 2b | |||
| Treatment | |||
| Nonrecipients | 1.00 | … | … |
| Nirmatrelvir/ritonavir recipients | 0.28 | .22–.36 | <.001 |
| Age, per year | 1.16 | 1.15–1.18 | <.001 |
| Previous COVID-19 | |||
| No previous SARS-CoV-2 infection | 1.00 | … | … |
| Previous SARS-CoV-2 infection | 0.32 | .14–.64 | .003 |
| Vaccination status | |||
| Unvaccinated | 1.00 | … | … |
| Vaccination: 2, 3, or 4 doses ≤6 mo before index SARS-CoV-2 infection | 0.42 | .32–.55 | <.001 |
| Vaccination: 2, 3, or 4 doses >6 mo before index SARS-CoV-2 infection | 0.25 | .18–.34 | <.001 |
Abbreviation: ICU, intensive care unit.
aModel 1: hospitalization without ICU admission, clinical deterioration, or death vs no hospitalization, ICU admission, clinical deterioration, or death.
bModel 2: death with or without ICU admission or clinical deterioration vs no hospitalization, ICU admission, clinical deterioration, or death.